{"filings":[{"id":724077,"accession_number":"0001193125-26-245484","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2026-05-28T21:06:28+00:00","items":["5.02"],"status":"ready","headline":"Allogene appoints Zachary Roberts as CEO effective July 1, 2026; David Chang becomes non-employee director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Zachary Roberts, M.D., Ph.D., currently EVP R&D and CMO, named President and CEO effective July 1, 2026.","Dr. Roberts receives $680k base salary, 60% target bonus, options for 476,190 shares, and 134,530 RSUs.","Outgoing CEO David Chang, M.D., Ph.D. will remain on the Board as a non-employee director after June 30, 2026.","Dr. Chang eligible for severance benefits under Allogene's Change in Control and Severance Benefit Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":67881,"accession_number":"0001628280-26-034583","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2026-05-13T20:03:30+00:00","items":["1.01","1.02","2.02","9.01"],"status":"ready","headline":"Allogene Q1 net loss $42.6M; ALPHA3 interim shows 58% MRD clearance; cash runway extended to Q1 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Terminated exclusive license with Overland; retains ~3% equity; no termination payments.","ALPHA3 interim: 58.3% MRD clearance in cema-cel arm vs 16.7% observation; no CRS/ICANS/GvHD.","Q1 net loss $42.6M ($0.18/sh); operating cash expense guidance raised to ~$165M.","Cash $266.9M; April public offering grossed $200.4M; runway into Q1 2029.","ALLO-329 Phase 1 RESOLUTION dosed 9 patients; initial signs of activity; next update Q4 2026."],"consensus_eps_estimate":-0.1942,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95088,"accession_number":"0001193125-26-157140","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Allogene prices $175M public offering of 87.5M shares at $2.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 87,500,000 shares at $2.00/share; gross proceeds ~$175M before discounts and expenses.","Underwriters granted 30-day option to buy up to 13,125,000 additional shares at same price.","Closing expected on or about April 16, 2026, subject to customary conditions.","Net proceeds for general corporate purposes including clinical trials and R&D.","Goldman Sachs, Jefferies, and TD Cowen act as joint bookrunners; Piper Sandler and William Blair also joint bookrunners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95087,"accession_number":"0001193125-26-152866","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allogene Therapeutics launches underwritten public offering, suspends ATM sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company announced proposed underwritten public offering of common stock on April 13, 2026.","Sales under existing ATM agreement with TD Securities are suspended pending new prospectus.","No offering size or pricing details disclosed in the 8-K; further supplement expected.","Proceeds intended for general corporate purposes; dilution to existing shareholders anticipated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95086,"accession_number":"0001193125-26-151999","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allogene's cema-cel shows 41.6% MRD clearance advantage in ALPHA3 Phase 2 interim","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["58.3% (7/12) of cema-cel patients achieved MRD negativity vs 16.7% (2/12) in observation arm.","No CRS, ICANS, or GvHD reported; 10 of 12 cema-cel patients managed fully outpatient.","Plasma ctDNA decreased 97.7% median in cema-cel arm vs 26.6% increase in observation at Day 45.","Cema-cel arm had more aggressive disease (100% stage III-IV, 41.7% IPI 4-5) than observation.","ALPHA3 targets ~220 patients; enrollment complete by end 2027; interim EFS mid-2027, primary mid-2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107903,"accession_number":"0001628280-26-017230","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene Q4 net loss $38.8M; cash runway into Q1 2028; cema-cel ALPHA3 interim April 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $38.8M ($0.17/share); FY 2025 net loss $190.9M ($0.87/share).","Cash, equivalents, investments $258.3M; runway extended into Q1 2028 via disciplined spending, $23.7M escrow return.","Pivotal Phase 2 ALPHA3 trial of cema-cel in 1L LBCL; interim futility analysis (MRD clearance, safety) planned April 2026.","Phase 1 RESOLUTION trial of ALLO-329 (CD19/CD70 CAR T) in autoimmune diseases; proof-of-concept data expected June 2026.","ALLO-316 TRAVERSE trial in RCC completed Phase 1b enrollment; exploring partnering opportunities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124316,"accession_number":"0001628280-25-050227","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene Therapeutics Reports Q3 2025 Net Loss of $41.4M, Cash of $277.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 net loss $41.4M ($0.19 per share), cash $277.1M, cash runway into 2H 2027.","Phase 2 ALPHA3 trial for cema-cel in LBCL on track for futility analysis in 1H 2026.","Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease enrolling, proof-of-concept data expected 1H 2026.","Phase 1 TRAVERSE trial for ALLO-316 in RCC shows durable responses; next phase under evaluation.","Additional ALPHA3 trial sites in Australia and South Korea expected to open early 2026."],"consensus_eps_estimate":-0.2277,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124315,"accession_number":"0001628280-25-044828","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allogene reports patent infringement lawsuit against licensor Cellectis by Factor Bioscience","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Factor Bioscience filed a complaint in Delaware against Cellectis and AstraZeneca on Sept 26, 2025, alleging TALEN gene-editing patent infringement.","Allogene relies on Cellectis's TALEN technology for allogeneic CAR T candidates including cema-cel and ALLO-316.","Cellectis notified Allogene on October 6, 2025, and intends to vigorously defend against the claims.","Factor may also assert direct claims against Allogene as a commercial user of the disputed technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140991,"accession_number":"0001737287-25-000087","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene Q2 net loss $50.9M; highlights ALPHA3 trial progress and ALLO-329 autoimmune initiation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $50.9M ($0.23/share) for Q2 2025; cash and investments $302.6M as of June 30, 2025.","Pivotal ALPHA3 trial for cema-cel in LBCL proceeding as randomized two-arm study; futility analysis on track for 1H 2026.","Phase 1 RESOLUTION trial with ALLO-329 initiated in rheumatology autoimmune diseases; proof-of-concept data expected 1H 2026.","ALLO-316 completed Phase 1b enrollment in RCC; FDA aligned on pivotal trial design, partnership discussions possible.","Cash runway projected into 2H 2027; 2025 guidance: cash burn ~$150M, GAAP OpEx ~$230M."],"consensus_eps_estimate":-0.279,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140990,"accession_number":"0001193125-25-171091","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allogene drops ALLO-647 after Grade 5 death; pivots to Dagger platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Grade 5 hepatic failure from adenovirus attributed to ALLO-647; FC+ALLO-647 arm closed in ALPHA3 study.","ALLO-647 removed from all ongoing and pipeline programs; no trial includes it.","ALPHA3 proceeds as randomized trial of cema-cel with standard FC vs observation.","Futility analysis on MRD conversion expected in first half 2026.","Over 50 clinical sites activated; next-gen AlloCAR T uses Dagger Platform to reduce lymphodepletion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158760,"accession_number":"0001737287-25-000070","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Allogene shareholders elect three Class I directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elizabeth Barrett, Arie Belldegrun, and David Chang elected as Class I directors with >131M votes for each.","Advisory vote on NEO compensation approved: 139.9M for, 14.2M against, 3.2M abstain.","Ratification of Ernst & Young as auditor for FY2025: 190.1M for, 414.6K against.","All proposals passed with no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158759,"accession_number":"0001737287-25-000063","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene Q1 net loss $59.7M; ALPHA3 milestone delayed to 1H 2026; cash runway to 2H 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $59.7M ($0.28/sh); R&D $50.2M, G&A $15M; cash, equivalents & investments $335.5M.","ALPHA3 (cema-cel) lymphodepletion/futility analysis shifted to 1H 2026; >250 patients consented, ~50 sites activated.","ALLO-329 RESOLUTION basket trial in AID starts mid-2025; proof-of-concept data moved to 1H 2026.","ALLO-316 TRAVERSE updated Phase 1b results to be presented at ASCO June 1, 2025.","Cash runway extended into 2H 2027; 2025 guidance: cash burn ~$150M, GAAP op ex ~$230M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177163,"accession_number":"0001737287-25-000035","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene reports Q4 net loss $59.9M; cash $373.1M; pipeline milestones 2025-2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $59.9M ($0.28/share); FY net loss $257.6M ($1.32/share); R&D expense $45M Q4.","Cash & investments $373.1M; cash runway into 2H 2026; 2025 guidance: ~$170M cash burn.","ALPHA3 pivotal trial for cema-cel in 1L LBCL: 40 sites activated; futility analysis mid-2025; primary EFS data YE2026.","ALLO-329 autoimmune: IND cleared; RESOLUTION basket trial start mid-2025; proof-of-concept data YE2025.","ALLO-316 RCC: Phase 1b expansion fully enrolled; data mid-2025; RMAT designation received."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177162,"accession_number":"0001193125-25-035162","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Allogene expands collaboration with Foresight for MRD companion diagnostic; commits $37.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended agreement covers MRD assay development as companion diagnostic for cema-cel in EU, UK, Canada, Australia.","Allogene to fund approximately $37.3 million for assay development, milestone payments, and clinical sample testing.","Parties will use commercially reasonable efforts to obtain regulatory approval for respective products.","Each party retains ownership of its background IP and improvements; termination rights unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177161,"accession_number":"0001193125-25-014985","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Allogene Therapeutics officer Timothy Moore to depart Feb 28, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Timothy Moore leaving employment on February 28, 2025; departure treated as termination without cause.","Eligible for cash severance and COBRA reimbursement under the company's Change in Control and Severance Benefit Plan, subject to release.","Company intends to enter into a consulting agreement with Moore, terms to be mutually agreed.","No immediate replacement for Moore has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193943,"accession_number":"0001737287-24-000075","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Allogene discontinues enrollment in Phase 1 cema-cel CLL trial due to slow accrual","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued the Phase 1 cohort in ALPHA2 trial for cema-cel in relapsed/refractory CLL after BTKi/BCL2i therapy.","Enrollment slower than anticipated due to emergence of new alternative treatment options.","Interest among investigators remains high but company is reallocating resources to other pipeline programs.","No financial impact or guidance changes disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193942,"accession_number":"0001737287-24-000072","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene Q3 2024 net loss $66.3M; cash $403.4M; cash runway into 2H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $66.3M ($0.32/share) including $13.4M stock-based comp and $10.7M impairment; R&D $44.7M, G&A $16.3M.","Ended Q3 with $403.4M cash; maintains 2024 cash burn ~$200M and runway into 2H 2026.","Pivotal ALPHA3 cema-cel trial in 1L LBCL: ~30 sites active; enrollment completion expected 1H 2026; BLA submission targeted 2027.","ALLO-329 (CD19/CD70 dual CAR) for autoimmune disease: IND planned Q1 2025, proof-of-concept by YE 2025.","ALLO-316 for RCC received RMAT designation; Phase 1 TRAVERSE showed 50% ORR in CD70 TPS ≥50% patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":22000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193941,"accession_number":"0001737287-24-000062","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["5.05","9.01"],"status":"ready","headline":"Allogene Therapeutics amends Code of Business Conduct and Ethics","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Updates insider trading policy, antitrust restrictions, and conflicts-of-interest procedures.","Expands fair dealing obligations, gift/entertainment restrictions, and data privacy/cybersecurity requirements.","Adds express requirement to comply with all other Company policies supporting the Code.","Applies to all directors, officers, employees, and certain consultants/contractors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210265,"accession_number":"0001737287-24-000055","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Allogene Q2 net loss $66.4M ($0.35/sh); initiated pivotal ALPHA3 trial for cema-cel","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $66.4M ($0.35 per share) includes $13.6M stock-based comp and $5.0M impairment.","Cash, equivalents and investments $444.6M as of June 30, 2024; runway into 2H 2026.","Pivotal Phase 2 ALPHA3 trial for cema-cel in 1L LBCL initiated; enrollment completion expected 1H 2026, BLA submission 2027.","ALLO-329 (CD19/CD70 dual CAR) IND on track for Q1 2025 in autoimmune disease; proof-of-concept by YE 2025.","ALLO-316 Phase 1 TRAVERSE data update with ~20 RCC patients planned for YE 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":22000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228566,"accession_number":"0001737287-24-000050","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Allogene appoints new principal accounting officer; shareholders elect directors and ratify auditor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annie Yoshiyama appointed principal accounting officer, replacing Geoffrey Parker; Parker remains CFO.","Yoshiyama previously VP Finance & Controller at AN2 Therapeutics and CAO at Tricida.","Shareholders elected four Class III directors (DeYoung, Humer, Kazam, Mayo) to serve until 2027.","Advisory say-on-pay approved with 119.7M votes for, 16.3M against.","Ernst & Young ratified as independent auditor for fiscal year ending December 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228565,"accession_number":"0001737287-24-000046","cik":1737287,"company_name":"Allogene Therapeutics, Inc.","ticker":"ALLO","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Allogene restructures JV; ownership diluted to 15.4%, license royalty amended to flat mid-single-digit","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["JV acquires Overland US (lead asset OL-101, autologous GPRC5D-BCMA CAR-T for multiple myeloma).","Overland's ownership in JV increases to 69.63%; Allogene's drops to 15.37% after share incentive plan increase.","Exclusive license royalty changed to flat mid single-digit on net sales in territory, no longer subject to reductions.","Allogene gains termination rights for funding default or failure to initiate tech transfer; license auto-terminates if Allogene's ownership <7.5% unless mutual plan agreed.","Overland distributes all JV shares to HH BioPharma Holdings (HBP), which gets 3 of 5 board seats."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":774872013.1422222,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}